-
Something wrong with this record ?
LC-MSn and HR-MS characterization of secondary metabolites from Hypericum japonicum Thunb. ex Murray from Nepalese Himalayan region and assessment of cytotoxic effect and inhibition of NF-κB and AP-1 transcription factors in vitro
G. Peron, J. Hošek, S. Rajbhandary, DR. Pant, S. Dall'Acqua,
Language English Country Great Britain
Document type Journal Article
- MeSH
- Anti-Inflammatory Agents pharmacology MeSH
- Biological Assay MeSH
- Cell Line MeSH
- Chromatography, Liquid MeSH
- Flavonoids pharmacology MeSH
- Phloroglucinol pharmacology MeSH
- Mass Spectrometry MeSH
- Hydroxybenzoates pharmacology MeSH
- Inhibitory Concentration 50 MeSH
- Humans MeSH
- NF-kappa B p50 Subunit antagonists & inhibitors MeSH
- Antineoplastic Agents pharmacology MeSH
- Plant Extracts pharmacology MeSH
- THP-1 Cells MeSH
- Transcription Factor AP-1 antagonists & inhibitors MeSH
- Hypericum chemistry MeSH
- Cell Survival MeSH
- Xanthones pharmacology MeSH
- Inflammation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Nepal MeSH
Hypericum japonicum Thunb. ex Murray is traditionally used in Nepal to treat several diseases, among whom inflammation and acute pain. Although several secondary metabolites from the same Hypericum species have been already characterized and considered for their pharmacological use, an exhaustive phytochemical characterization of H. japonicum from Nepal is lacking, as well as the assessment of its potential pharmacological properties. Hence, the aims of this study were the characterization of a methanolic extract of H. japonicum (HJME) collected from the Northern region of Nepal by LC-MSn and UPLC-QTOF. The assessment of in vitro inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) transcription factors and HJME's cytotoxic effect on human cell lines was performed to evaluate the potential use of this herb as a source of anti-inflammatory and cytotoxic lead compounds. Fifty-seven phytoconstituents were identified, being mainly flavonoids, phloroglucinols, phenolic acids and xanthones. Although compounds characteristic of H. japonicum were detected (quercetin, quercetin-7-O-α-l-rhamnoside, quercitrin and hyperoside), several others are here reported for the first time in this species. The results from bioassays indicated that HJME could significantly reduce the viability of human THP-1 cells (IC50 = 5.4 ± 1.1 μg mL-1), showing the promising potential of HJME as anti-tumor agent. Furthermore, HJME significantly decreased the activation of both NF-κB and AP-1 at the concentration of 2 μg mL-1. Overall, these data suggest that H. japonicum from Nepal could be used as a source of potential natural anti-inflammatory and anti-tumor lead compounds.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006170
- 003
- CZ-PrNML
- 005
- 20200526152448.0
- 007
- ta
- 008
- 200511s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2019.06.042 $2 doi
- 035 __
- $a (PubMed)31288189
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Peron, Gregorio $u Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy. Electronic address: perongregorio@yahoo.it.
- 245 10
- $a LC-MSn and HR-MS characterization of secondary metabolites from Hypericum japonicum Thunb. ex Murray from Nepalese Himalayan region and assessment of cytotoxic effect and inhibition of NF-κB and AP-1 transcription factors in vitro / $c G. Peron, J. Hošek, S. Rajbhandary, DR. Pant, S. Dall'Acqua,
- 520 9_
- $a Hypericum japonicum Thunb. ex Murray is traditionally used in Nepal to treat several diseases, among whom inflammation and acute pain. Although several secondary metabolites from the same Hypericum species have been already characterized and considered for their pharmacological use, an exhaustive phytochemical characterization of H. japonicum from Nepal is lacking, as well as the assessment of its potential pharmacological properties. Hence, the aims of this study were the characterization of a methanolic extract of H. japonicum (HJME) collected from the Northern region of Nepal by LC-MSn and UPLC-QTOF. The assessment of in vitro inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) transcription factors and HJME's cytotoxic effect on human cell lines was performed to evaluate the potential use of this herb as a source of anti-inflammatory and cytotoxic lead compounds. Fifty-seven phytoconstituents were identified, being mainly flavonoids, phloroglucinols, phenolic acids and xanthones. Although compounds characteristic of H. japonicum were detected (quercetin, quercetin-7-O-α-l-rhamnoside, quercitrin and hyperoside), several others are here reported for the first time in this species. The results from bioassays indicated that HJME could significantly reduce the viability of human THP-1 cells (IC50 = 5.4 ± 1.1 μg mL-1), showing the promising potential of HJME as anti-tumor agent. Furthermore, HJME significantly decreased the activation of both NF-κB and AP-1 at the concentration of 2 μg mL-1. Overall, these data suggest that H. japonicum from Nepal could be used as a source of potential natural anti-inflammatory and anti-tumor lead compounds.
- 650 _2
- $a antiflogistika $x farmakologie $7 D000893
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a biotest $7 D001681
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a chromatografie kapalinová $7 D002853
- 650 _2
- $a flavonoidy $x farmakologie $7 D005419
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydroxybenzoáty $x farmakologie $7 D062385
- 650 _2
- $a třezalka $x chemie $7 D020902
- 650 _2
- $a zánět $7 D007249
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a hmotnostní spektrometrie $7 D013058
- 650 _2
- $a NF-kappa B - podjednotka p50 $x antagonisté a inhibitory $7 D052002
- 650 _2
- $a floroglucinol $x farmakologie $7 D010696
- 650 _2
- $a rostlinné extrakty $x farmakologie $7 D010936
- 650 _2
- $a THP-1 buňky $7 D000074084
- 650 _2
- $a transkripční faktor AP-1 $x antagonisté a inhibitory $7 D018808
- 650 _2
- $a xantony $x farmakologie $7 D044004
- 651 _2
- $a Nepál $7 D009390
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hošek, Jan $u Division of Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. Electronic address: jan.hosek@upol.cz.
- 700 1_
- $a Rajbhandary, Sangeeta $u Central Department of Botany, Tribhuvan University, 44600 Kirtipur, Kathmandu, Nepal. Electronic address: s.rajbhandary@cdbtu.edu.np.
- 700 1_
- $a Pant, Deepak Raj $u Central Department of Botany, Tribhuvan University, 44600 Kirtipur, Kathmandu, Nepal. Electronic address: drpant_agbot@yahoo.com.
- 700 1_
- $a Dall'Acqua, Stefano $u Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy. Electronic address: stefano.dallacqua@unipd.it.
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 174, č. - (2019), s. 663-673
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31288189 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526152444 $b ABA008
- 999 __
- $a ok $b bmc $g 1525028 $s 1096226
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 174 $c - $d 663-673 $e 20190702 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20200511